Tau Protein
Tau is well established as a microtubule-associated protein in neurons. They have roles primarily in maintaining the stability of microtubules in axons and are abundant in the neurons of the central nervous system (CNS). However, under pathological conditions, aberrant assembly of tau into insoluble aggregates is accompanied by synaptic dysfunction and neural cell death in a range of neurodegenerative disorders, collectively referred to as tauopathies.
All Product Categories
-
Tau Protein Related Products (217)
Related Products (217)
-
Antibodies (5)
-
Tau-aggregation-IN-3
0 ImagesCat. No.: HY-161448CAS No.: 3032869-59-0Tau-aggregation-IN-3 (compound 9) a Tau protein aggregation inhibitor (TAI). Tau-aggregation-IN-3 shows activity in cell-based aggregation inhibition experiments (EC50=4.816 μM). Tau-aggregation-IN-3 can be used in Alzheimer's disease research.
-
Aha1/Hsp90-IN-2
0 ImagesCat. No.: HY-179377Aha1/Hsp90-IN-2 is a selective inhibitor of the Hsp90/Aha1 interaction, with its IC50 being 1.46 μM. Aha1/Hsp90-IN-2 inhibits the activation of Hsp90 ATPase activity mediated by Aha1 by specifically blocking the binding of Hsp90 to Aha1, thereby reducing tau protein aggregation. Aha1/Hsp90-IN-2 can be used for the study of neurodegenerative diseases, such as Alzheimer's disease.
-
Gosuranemab (powder)
0 ImagesCat. No.: HY-P99648ACAS No.: 1788032-39-2Synonyms: BMS-986168 (powder); IPN007 (powder); BIIB092 (powder)Gosuranemab (BMS-986168; IPN007; BIIB092) (powder) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab (powder) neutralizes the extracellular tau protein, inhibiting the spread and aggregation of pathological tau protein. Gosuranemab (powder) can be used for the research of progressive supranuclear palsy and early Alzheimer’s disease.
-
Tau ligand-2
0 ImagesCat. No.: HY-181083CAS No.: 3046416-94-5Tau ligand-2 is a tau aggregate ligand with a Ki value of 0.99 nM. Radiolabeled (18F) Tau ligand-2 serves as a PET tracer. Tau ligand-2 is applicable to research related to Alzheimer's disease.
-
TAU-IN-2
0 ImagesCat. No.: HY-164341CAS No.: 1417823-63-2TAU-IN-2 (Example 25) is a TAU inhibitor with an EC50 value of 7.7 nM. TAU-IN-2 can be used in the study of neurodegenerative diseases.
-
LDN-193665
0 ImagesCat. No.: HY-120744CAS No.: 1289638-16-9LDN-193665 is a Tau kinase inhibitor with tauopathy-modifying activity. LDN-193665 inhibits Tau phosphorylation, improves tauopathy in animal models, reduces Sarkosyl-insoluble Tau, and restores memory. It may be necessary to simultaneously target multiple kinases to effectively inhibit tauopathies.
-
TTBK1/2-IN-1
0 ImagesCat. No.: HY-172542CAS No.: 2342571-09-7TTBK1/2-IN-1 (compound 3) is a potent Tau tubulin kinase 1 (TTBK1) and TTBK2 inhibitor with IC50s of 816 nM and 384 nM, respectively.
-
TTBK1-IN-3
0 ImagesCat. No.: HY-157310CAS No.: 2735015-52-6TTBK1-IN-3 (Compound 18) is a potent inhibitor of TTBK1, with a biochemical IC₅₀ of 18 nM and a cellular IC₅₀ of 259 nM. TTBK1-IN-3 can be used for research on Alzheimer's disease.
-
Tau Protein Phosphorylation-IN-1
0 ImagesCat. No.: HY-175841CAS No.: 3075165-36-2Tau Protein Phosphorylation-IN-1 is a tau protein phosphorylation inhibitor that potently protects PC12 cells against Aβ25–35-induced cytotoxicity (EC50 = 1.93 μM), and can penetrate the blood-brain barrier (BBB).Tau Protein Phosphorylation-IN-1 reverses the hyperphosphorylation of tau, significantly inhibits the expression of certain immune-related cytotoxic factors, suppresses the MAPK and NF-κB signaling pathways, and significantly inhibits the expression of RAGE and the apoptosis factors Bax/Bcl-2, both in vitro and in vivo. Tau Protein Phosphorylation-IN-1 relieves nerve damage, and improves learning and memory in an Alzheimer’s disease (AD) mouse model. Tau Protein Phosphorylation-IN-1 can be used for AD research.
-
AChE/MAO-B-IN-9
0 ImagesCat. No.: HY-181861CAS No.: 2341935-88-2AChE/MAO-B-IN-9 (Compound E12) is an orally active, selective, reversible, non-competitive AChE and MAO-B inhibitor, with an IC50 of 0.156 μM against electric eel AChE. AChE/MAO-B-IN-9 inhibits Aβ40/42 fibril formation, promotes Aβ fibril depolymerization, and inhibits Tau protein fibril formation. AChE/MAO-B-IN-9 exerts antioxidant and neuroprotective effects, and improves scopolamine (HY-N0296)-induced memory impairment in mice. AChE/MAO-B-IN-9 can be used for the research of Alzheimer's disease.
-
AF710B
0 ImagesCat. No.: HY-116586AF710B is an orally effective allosteric agonist for the M1 muscarinic receptor and σ1 receptor. AF710B activates the downstream phosphorylated ERK1/2 and phosphorylated CREB signaling pathways. AF710B simultaneously improves cognitive function and alleviates the core pathological features of Alzheimer's disease, including Aβ deposition, excessive Tau phosphorylation and neuroinflammation. AF710B is applicable to the research of Alzheimer's disease.
-
(Pyr3)-Amyloid β-Protein (3-42)
0 ImagesCat. No.: HY-P4882CAS No.: 183449-57-2(Pyr3)-Amyloid β-Protein (3-42) is an N-terminally truncated pyroglutamylated β-amyloid peptide. (Pyr3)-Amyloid β-Protein (3-42) forms stable β-sheet structures across different pH values, co-oligomerizes with Aβ1-42 to form cytotoxic oligomers, induces tau-dependent cytotoxicity and neuronal loss, inhibits hippocampal LTP, and exhibits stronger protease resistance. (Pyr3)-Amyloid β-Protein (3-42) exists in the brain tissues of human Alzheimer's disease patients, correlates with the pathogenesis of Alzheimer's disease, and follows a unique, faster oligomerization pathway. (Pyr3)-Amyloid β-Protein (3-42) can be used in Alzheimer's disease-related research.
-
ADEL-Y01
0 ImagesCat. No.: HY-P992172ADEL-Y01 is a humanized and parental murine blood-brain barrier-penetrating monoclonal antibody against tau-acK280. ADEL-Y01 specifically recognizes tau-acK280 and its surrounding residues, mediates the neutralization and phagocytosis of acetylated tau aggregates, and interferes with the activity of pathological tau protein. ADEL-Y01 prevents the progression of tauopathies, increases neuronal survival rate, reduces tau-related pathological changes, and improves memory impairment. ADEL-Y01 can be used in research related to Alzheimer's disease and tauopathies.
-
VY7523
0 ImagesCat. No.: HY-P992484VY7523 is a monoclonal antibody and a selective inhibitor of pathological Tau. VY7523 reduces the propagation of pathogenic Tau in transgenic mouse models. VY7523 can be used in the research of Alzheimer's disease. The isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
-
Tau Peptide (1-16) (human)
0 ImagesCat. No.: HY-P4923CAS No.: 2022956-53-0Tau Peptide (1-16) (human) is aTau fragment.
-
MG-1102
0 ImagesCat. No.: HY-160481CAS No.: 2567913-75-9MG-1102 is first-in-class dual binder of monomeric tau and pre-miRNA-146a. MG-1102 shows specific inhibition of miRNA146a with IC50s of 0.21 mM and 0.36 mM specific inhibition of doublelabeled pre-miRNA146a and mono-labeled pre-miRNA146a, respectively. MG-1102 interacts with tau monomers with a Kd of 3.21 mM by surface plasmon resonance (SPR). MG-1102 is a potential multi-target-directed ligands (MTDLs) for Alzheimer’s disease (AD).
-
CLR01 sodium
0 ImagesCat. No.: HY-182304CAS No.: 1338489-62-5CLR01 sodium is a blood-brain barrier-permeable anti-aggregation agent. CLR01 sodium inhibits the de novo aggregation of Amyloid-β 40/42, α-synuclein, IAPP, tau protein and SOD1. CLR01 sodium reduces amyloid plaque burden in the cortex of triple-transgenic mice and improves the memory and motor abilities of these mice. CLR01 sodium can be used in research related to Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).
-
RI-AG03
0 ImagesCat. No.: HY-P10861RI-AG03 is a proteolytically stable tau aggregation inhibitor that crosses the blood-brain barrier and exhibits oral efficacy. RI-AG03 inhibits tau aggregation and promotes the formation of alternative amorphous aggregates that are non-amyloidogenic. RI-AG03 mediates cellular uptake through direct membrane penetration and macropinocytosis, and its conjugation with cell-penetrating peptide sequences (CPPs) enhances the binding of cells to liposomes. RI-AG03 suppresses aggregation-dependent neurodegenerative and behavioral phenotypes, and extends the lifespan of Drosophila models of tauopathy. RI-AG03 can be used for research on tau-related diseases such as Alzheimer's disease.
